Inner Mongolia Furui Medical Technology Co., Ltd. 2025 Annual Report Summary

Stock Code: 300049 Stock Short Name: Furuimedicine Announcement No.: 2026-004

I. Important Notices

The summary of this annual report is drawn from the full annual report. To fully understand the Company’s operating results, financial condition, and future development plans, investors shall read the full annual report carefully in the media designated by the CSRC.

All directors have attended the board meeting that reviewed this report.

The audit opinion of the accounting firm Dacheng (Special General Partnership) on the Company’s financial statements for this year is: a standard unqualified opinion.

Notice of Non-Standard Audit Opinion

□ Applicable √ Not applicable

The Company was not profitable at the time of listing and is not currently able to achieve profitability

□ Applicable √ Not applicable

Profit distribution proposal for the reporting period considered and approved by the Board of Directors, or a proposal for conversion of capital reserve into share capital

√ Applicable □ Not applicable

The profit distribution proposal approved by the Board of Directors through this Board meeting is: based on 264,975,900 as the basis, distribute cash dividends of RMB 1.5 per 10 shares to all shareholders (including tax), issue bonus shares of 0 shares per 10 shares (including tax), and convert 0 shares per 10 shares to all shareholders from the capital reserve.

Profit distribution proposal for preferred shares for the reporting period approved by the Board of Directors

□ Applicable □ Not applicable

II. Basic Information of the Company

1. Company Profile

■

2. Description of Major Business or Products for the Reporting Period

3. Production and sales of pharmaceutical products

The Company’s main drugs are compound Bie Jia Soft Liver Tablets. The main uses of compound Bie Jia Soft Liver Tablets are: soften and disperse hard masses, resolve blood stasis, detoxify, and tonify qi and nourish blood; used for chronic hepatitis and liver fibrosis as well as early cirrhosis of the liver. They belong to the syndrome of blood stasis obstructing the collaterals, deficiency of qi and blood, with residual heat toxin not fully eliminated. They are a national patented product. At the same time, they are the first anti-liver fibrosis drug approved by the National Medical Products Administration (NMPA). They are prescription drugs included in the National Reimbursement Drug List. After more than 20 years of market validation, Soft Liver Tablets have become the number-one brand of medication for anti-liver fibrosis and have wide market recognition.

In 2025, the Company’s own pharmaceutical business achieved annual operating revenue of RMB 288 million. During the deep implementation of the managed-care medical strategy, the Company further deepened the “products + services” two-wheel-drive development model and built a diversified, full-scenario business layout. On the one hand, the Company continued to focus on traditional channels for pharmaceutical sales, optimized channel management, ensured stable supply of core drugs, and laid a solid foundation for business development. On the other hand, the Company focused on patient needs. By relying on the Company’s internet hospital platform to promote whole-course liver disease management, it also drove steady growth in terminal sales of liver disease drugs, injecting new momentum into long-term, sustainable growth of its own pharmaceutical business.

2. R&D and sales of diagnostic equipment

The Company’s main diagnostic products are the FibroScan? series of liver fibrosis and liver fat degeneration diagnostic instruments, as well as the FibroMeter series of blood test analysis tools for assessing chronic liver diseases and the FibroView data management software辅助 FibroScan? for辅助FibroScan? data management. The FibroScan? series includes multiple products such as FibroScan? 630, FibroScan? 530, FibroScan? PRO, FibroScan? Handy, and FibroScan? BOX. This product line is the world’s first set of non-invasive, real-time diagnostic equipment that quantifies liver stiffness using the transient elastography technology and has been clinically validated. It has obtained certifications such as the EU CE, the U.S. FDA, and China’s NMPA. The device is driven by cutting-edge patented technologies, including LSM (liver stiffness measurement), SSM (spleen stiffness measurement) and CAP? (controlled attenuation parameter) based on VCTE? (vibration-controlled transient elastography) technology. It can be used to assess liver fibrosis, portal hypertension, and liver fat degeneration. FibroScan? has been included in liver disease detection guidelines by multiple authoritative organizations such as the World Health Organization (WHO), the European Association for the Study of the Liver (EASL), the Asia-Pacific Association for the Study of the Liver (APASL), and the American Association for the Study of Liver Diseases (AASLD), and it is also used as an officially recommended liver elastography testing device. FibroScan? CAP has been approved by the U.S. FDA, marking a major breakthrough of FibroScan? in the field of fatty liver diagnosis and making FibroScan? an important tool for long-term clinical management of patients with fatty liver.

In 2025, the Company continued to focus on the diagnosis and treatment field of metabolism-related fatty liver disease (MAFLD). It centered on the establishment of a system for precise screening of the disease, disease course monitoring, and treatment assessment. It steadily deepened clinical research collaboration with global liver disease academic societies, and promoted the orderly application and penetration of FibroScan? non-invasive diagnostic technology in medical institutions at all levels and health management organizations, thereby consolidating the foundation for business development.

First, it increased R&D investment to advance product optimization and value upgrading: in line with the trend toward smaller and more portable devices, the Company’s independently developed liver disease patient management platform LHM (Liver Health Management) improves standardized management of liver disease patients by enhancing the FibroScan? device’s standardized management capabilities, improves clinical diagnosis and treatment efficiency and patients’ ability for whole-course management, and consolidates the Company’s global market influence in the field of liver disease diagnosis. Second, it deepened strategic synergy to expand the boundaries of commercial applications. In 2025, the Company announced a further deepening of cooperation with the global pharmaceutical company Boehringer Ingelheim. The two parties will integrate Echosens’ non-invasive testing technologies with Boehringer Ingelheim’s expertise in liver disease R&D to jointly eliminate key barriers in disease awareness, real-world evidence, and clinical application levels. Third, it participated in the construction of industry standards to strengthen academic recognition. The Company actively participated in updates to global clinical practice guidelines for liver diseases and related fields. Relying on academic achievements accumulated in the earlier stage, it continued to provide clinical application data for the FibroScan? device. For details on literature and guideline data, please refer to the “Analysis of Core Competitiveness” section in this chapter.

During the reporting period, the Company’s medical device business achieved overall operating revenue of RMB 1.134 billion, representing an increase of 23.48% compared with the same period last year. Among them, revenue from equipment sales was RMB 625 million, accounting for 55.16%; revenue from per-use charging, leasing, and other income was RMB 509 million, accounting for 44.84%. The Echosens company achieved net profit of RMB 250 million, representing an increase of 31.34% compared with the same period last year. As of the end of the reporting period, Echosens had installed FibroScan? GO, BOX, and Handy—products using the per-use charging and leasing model—totaling 1,691 units globally.

3. Medical services business

(1) Managed-care medical strategy

The Company firmly recognizes and implements the managed-care medical service model. Based on research into screening standards for people at high risk of liver cancer, it established new screening standards for liver cancer high-risk populations among primary healthcare institutions and occupational groups, promoted a new strategy for secondary prevention of liver cancer, and developed whole-course management solutions from screening and diagnosis to treatment. It practices the sacred mission of “keeping every family away from liver cancer.” By integrating medical devices, pharmaceuticals, and medical services, the Company helps improve the detection rate of liver diseases, treatment rates, and patient adherence. While achieving “mutual win for medical insurance, doctors, and patients,” it also strengthens scientific and effective management for patients with liver diseases and accelerates the Company’s transformation from products to services.

(2) Pediatric healthcare management

In its pediatric business, the Company adheres to the concept of “health management across the entire life cycle of children.” It supports tiered diagnosis and treatment to ensure accessibility and a public welfare segment that promotes universal benefit. It empowers primary healthcare institutions and doctors to provide basic medical services and basic public health services. With a solid foundation of cooperation with medical institutions such as the Affiliated Children’s Hospital of Zhejiang University School of Medicine, the Children’s Hospital affiliated with Fudan University, the Second West China Hospital of Sichuan University, and others, the Company actively promotes the downward transfer of high-quality pediatric medical resources and enhances the capacity of pediatric medical services at the primary level. Meanwhile, at the Company’s direct-operated store, the Wuhou Children’s Excellence Outpatient Department, it emphasizes children’s health management and rehabilitation during special periods of childhood to support the profitability segment of children’s health consumption.

3. Key Accounting Data and Financial Indicators

(1) Key accounting data and financial indicators for the past three years

Does the Company need to retrospectively adjust or restate prior-year accounting data?

□ Yes √ No

RMB

■

(2) Key accounting data by quarter

Unit: RMB

■

Whether the above financial indicators or the sum thereof has a material difference from the financial indicators related to the Company’s quarterly reports and semi-annual reports already disclosed

□ Yes √ No

4. Share Capital and Shareholder Information

(1) Number of common shareholders and number of preferred shareholders whose voting rights have been restored, and table of shareholding of the top 10 shareholders

Unit: shares

■

Shareholding of shareholders holding more than 5%, the top 10 shareholders, and the top 10 tradable shareholders without selling restrictions participating in the securities lending and borrowing (transfer and borrowing) business

□ Applicable √ Not applicable

Changes in the shareholding of the top 10 shareholders and top 10 tradable shareholders without selling restrictions due to reasons such as securities lent out/repaid under transfer and borrowing, compared with the previous period

□ Applicable √ Not applicable

Does the Company have arrangements for differences in voting rights

□ Applicable □ Not applicable

(2) Total number of preferred shareholders of the Company and table of shareholding of the top 10 preferred shareholders

There are no preferred shareholders with shareholding during the reporting period.

(3) Disclose property and control relationships between the Company and the actual controller in the form of a block diagram

■

5. Bond information outstanding as of the date of approval and issuance of the annual report

□ Applicable □ Not applicable

III. Important Matters

On December 16, 2025, the Company held the 16th meeting of the Eighth Board of Directors, which reviewed and approved proposals including “Proposal on the Company’s Issuance of H-Share Stock and Listing on The Stock Exchange of Hong Kong Limited” and “Proposal on the Company’s H-Share Stock Issuance and Listing Plan on The Stock Exchange of Hong Kong Limited,” etc. On January 5, 2026, the Company convened the first extraordinary general meeting of shareholders in 2026 to consider and approve the above proposals. For details, please refer to the relevant announcements disclosed on the website of Juchao Information.

Endless information and precise interpretation—available on the Sina Finance APP